Table 1

Baseline characteristics and outcomes after 2 years stratified for tapering strategy and the use of one or multiple csDMARDs at baseline

Tapering csDMARD first
(n=94)
Tapering TNF-inhibitor first
(n=95)
1 csDMARD
(n=64)
>1 csDMARD
(n=30)
1 csDMARD
(n=57)
>1 csDMARD
(n=38)
Baseline characteristics
 Age, mean (SD)56.9 (14.1)53.9 (14.2)57.9 (11.1)56.2 (10.0)
 Female, n (%)47 (73.4)19 (65.5)34 (59.7)24 (63.2)
 Symptom duration, mean (SD)6.54 (3.04)6.35 (4.31)7.69 (4.80)6.05 (3.47)
 RF, n (%)33 (55.9)16 (59.3)36 (67.9)20 (57.1)
 ACPA, n (%)41 (69.5)20 (76.9)41 (77.4)24 (70.6)
 DAS44, mean (SD)1.11 (0.52)1.00 (0.64)1.07 (0.54)0.81 (0.42)
 Boolean remission, n (%)23 (35.9)8 (26.7)22 (38.6)13 (34.2)
Outcomes after 2 years
 Cumulative flare rate, n(%)39 (60.9)18 (60.0)41 (71.9)18 (47.4)
 Completed tapering protocol, n (%)17 (26.6)12 (40.0)10 (17.5)10 (26.3)
 DMARD free remission, n(%)17 (26.6)2 (6.7)10 (17.5)0 (0)
  • ACPA, anticitrillunated protein antibody; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS44, disease activity score based on 44 joints; RF, rheumatoid factor; TNF, tumour necrosis factor.